CliffBio
biologic

Adbry

tralokinumab-ldrm

Loss of exclusivityJune 2036projected — 12-year biologic exclusivity estimate
CompanyLEO Pharma A/S

Drug detail

Brand nameAdbry
Active ingredienttralokinumab-ldrm
Strength300MG/2ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2024
Marketing statusRx

More from LEO Pharma A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Adbry patent cliff — loss of exclusivity June 2036 | CliffBio